The biomarker cut point will need to be validated in the larger study population, but seems to identify patients most likely to respond to pembrolizumab well.
The plant equivalents are the phytosterols, such as -sitosterol, stigmasterol, and brassicasterol; the latter compound is also used as a biomarker for algal growth.